A generic drug maker hoping to sell its own version of the popular cholesterol drug Zetia has succeeded in knocking out part of Schering-Plough's patent protection on the medication. A New Jersey federal judge on Monday invalidated items of protection that were added when Schering obtained a reissued patent in 2002, ruling the patent should not have been reissued because Schering already had a valid patent. The financial stakes are high: Last year alone, Schering reported worldwide sales of $2.2 billion for Zetia.
April 22, 2010 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
A generic drug maker hoping to sell its own version of the popular cholesterol drug Zetia has succeeded in knocking out part of Schering-Plough Corp.’s patent protection on the medication.
U.S. District Judge Jose Linares in Newark, N.J., on Monday invalidated items of protection that were added when Schering obtained a reissued patent in 2002, ruling the patent should not have been reissued because Schering already had a valid and enforceable patent.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
At NJM, a top-rated insurance company, we are seeking an Attorney on our Workers Compensation legal team with between 3 and 5 years of expe...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
